IVERIC bio

IVERIC bio Equity Growth

Delisted

The Year-over-Year Equity Growth of IVERIC bio (ISEE) as of Oct 28, 2026 is 48.33 %. In the previous year, Year-over-Year Equity Growth was 88.28 % — a change of -45.25% (lower).

Equity Growth

48.33 %

YoY

-45.25%

Last updated:

Year-over-Year Equity Growth of IVERIC bio is 2022 48.33 % . Year-over-Year Equity Growth of IVERIC bio was 2021 88.28 % . It decreases by -45.25% lower compared to the previous year.

The IVERIC bio Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2015
-59.25 USD
Jan 1, 2016
-257.84 USD
Jan 1, 2017
140.20 USD
Jan 1, 2018
225.86 USD
Jan 1, 2019
-5.49 USD
Jan 1, 2020
63.44 USD
Jan 1, 2021
88.28 USD
Jan 1, 2022
48.33 USD
The IVERIC bio Equity Growth history
YEAREquity GrowthYoY
48.33 %-45.25%
88.28 %+39.17%
63.44 %-1,255.37%
-5.49 %-102.43%
225.86 %+61.09%
140.20 %-154.38%
-257.84 %+335.14%
-59.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

IVERIC bio Stock analysis

What does IVERIC bio do? Iveric Bio Inc is a leading biopharmaceutical company specializing in the discovery and development of therapy options for eye diseases. The company was originally founded in 1989 as Ophthotech Corp. and is headquartered in New York City. Iveric Bio Inc aims to develop innovative treatments for eye diseases that can improve the lives of millions of people. The eye diseases that Iveric Bio Inc is fighting range from retinal diseases to degenerative eye diseases. Iveric Bio Inc has a strong business model, focusing on innovation to develop new treatment methods. The company invests in research and development to create a solid pipeline of new therapies, while also closely collaborating with the medical community to ensure that the therapies meet the needs of patients and doctors. Iveric Bio Inc's therapy options are focused on treating eye diseases such as age-related macular degeneration, diabetic retinopathy, and other retinal diseases. Iveric Bio Inc also focuses on preserving vision and improving the quality of life for people with glaucoma and other eye diseases. Iveric Bio Inc's portfolio currently includes two main products: Zimura and GATHER1. Zimura is a potentially groundbreaking medication developed for the treatment of dry age-related macular degeneration (AMD). It is currently being studied in late-stage clinical trials and could play an important role in the future of AMD treatment. GATHER1, the other main product of Iveric Bio Inc, is a clinical drug candidate developed for the treatment of geographic atrophy (GA). GA is an advanced form of dry AMD associated with the destruction of cells in the retina and a loss of vision. GATHER1 has been deemed promising in Phase II trials and is currently being tested in Phase III trials. Overall, Iveric Bio Inc has an excellent track record in the development of therapy options for eye diseases. The company has a wide range of treatment possibilities in the pipeline aimed at meeting the need for effective therapies for various eye diseases. Additionally, Iveric Bio Inc works closely with the medical community and other biopharmaceutical companies to share the latest research findings and advance the treatment of eye diseases. Overall, Iveric Bio Inc is an emerging biopharmaceutical company with a strong focus on research and development. The company has a strong business model and a robust pipeline of therapy options aimed at improving eye health and the quality of life for millions of people. IVERIC bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IVERIC bio stock

Year-over-Year Equity Growth of IVERIC bio is 48.33 % in 2022.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth IVERIC bio since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's IVERIC bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — IVERIC bio

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — IVERIC bio